本文選題：PRX-　切入點(diǎn)：生物制藥公司　出處：《國際藥學(xué)研究雜志》2017年05期 　論文類型：期刊論文

【摘要】：正Protalix生物制藥公司新臨床前研究證實(shí),PRX-102與市售有效酶替代療法聯(lián)用在Fabry小鼠模型上對小纖維神經(jīng)病變有陽性效果。PRX-102 1 mg/kg與阿加糖苷酶β(β-agalsidese,Fabrazyme)1 mg/kg聯(lián)用,和阿加糖苷酶α(α.agalsidase,Replagal)0.2 mg/kg比較,對給藥Fabry小鼠、不給藥Fabry小鼠和對照野生型小鼠的
[Abstract]:A new preclinical study by Protalix Biopharmaceutical Company confirmed that PRX-102 combined with marketable effective enzyme replacement therapy had positive effects on small fibrous neuropathy in Fabry mice model. PRX-1021 mg/kg was used in combination with 尾 -agalsidase 尾 (尾 -agalsideseto Fabrazyme 1 mg/kg), and was compared with agar glycosidase 偽 (偽. Agalsidase Replagalus 0. 2 mg/kg). For Fabry mice, Fabry mice and wild control mice
【分類號】：R965
，

本文編號：1572663